A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Clinical trial NCT06003231 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06003231
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung Ovarian Neoplasms Endometrial Neoplasms Head and Neck Neoplasms

Start date: 2023-11-14
Primary completion: 2026-03-27
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.